Clinical trial
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
NCT00165464 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165464 |
|---|---|
| Title | Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer |
| Official title | A Phase II Trial of Taxotere, Cisplatin, and Irinotecan in Advanced Esophageal and Gastric Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Beth Israel Deaconess Medical Center Brigham and Women's Hospital Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer, GE Junction Cancer |
| Intervention type | Drug |
| Interventions | Taxotere, Cisplatin, Irinotecan |
| Enrollment | 54 |
| Start date | Aug 1, 2001 |
| Primary completion | Mar 1, 2005 |
| Completion | Apr 1, 2009 |
| First posted | Sep 14, 2005 |
| Last update posted | Apr 28, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: